Abstract Prurigo is a reactive, hyperplastic skin condition characterized by pruritic papules, plaques, and/or nodules. The temporal classification includes acute/subacute and chronic disease (≥ 6 weeks), with different clinical variants, synonymies, and underlying etiological factors. The immunology of chronic prurigo shows similarities with atopic dermatitis due to the involvement of IL-4 and IL-13, IL-22, and IL-31. Treatment includes antihistamines, topical steroids, dupilumab, and JAK inhibitors. Several conditions manifest clinically as prurigo-like lesions, and the correct clinical diagnosis must precede correct treatment. Furthermore, chronic prurigos represent a recalcitrant and distressing dermatosis, and at least 50% of these patients have atopic diathesis, the treatment of which may induce adverse effects, especially in the elderly. The quality of life is significantly compromised, and topical treatments are often unable to control symptoms and skin lesions. Systemic immunosuppressants, immunobiologicals, and JAK inhibitors, despite the cost and potential adverse effects, may be necessary to achieve clinical improvement and quality of life. This manuscript reviews the main types of prurigo, associated diseases, their immunological bases, diagnosis, and treatment. reactive papules plaques andor or nodules acutesubacute acute subacute ≥ ( weeks, weeks , weeks) variants synonymies factors IL4 IL 4 IL- IL13, IL13 13, 13 IL-13 IL22, IL22 22, 22 IL-22 IL31. IL31 31. 31 IL-31 antihistamines steroids dupilumab inhibitors prurigolike like lesions Furthermore dermatosis 50 diathesis effects elderly compromised immunosuppressants immunobiologicals diseases bases IL1 1 IL-1 IL2 2 IL-2 IL3 3 IL-3 5

Abstract Background 5-Fluorouracil (5-FU) is a first-line drug to treat cutaneous field cancerization (CFC). There are few clinical trials with topical colchicine (COL). Objective To evaluate the effectiveness of 0.5% COL cream versus 5% 5-FU cream in the treatment of CFC. Method This was a randomized, open, self-controlled clinical trial. Forty-five patients (90 forearms), with three to ten actinic keratoses (AK) on each forearm, used 0.5% COL cream 2×/day for seven days on one forearm, and 5% 5-FU cream 2× /day, for 21 days, on the other forearm. The dosages were defined based on previous clinical trials for each drug. Adverse effects were evaluated after 14 days and outcomes after 90 days of inclusion. The primary outcome was complete AK clearance and the secondary outcomes were: partial clearance (≥50%), reduction in AK count, assessment of the Forearm Photoaging Scale (FPS), AK Severity Score (AKSS), and adverse effects. Results After 90 days, there was complete clearance of AK in 37% (95% CI 24%-49%) and partial clearance in 85% (95% CI 76%-93%) of the forearms treated with 5-FU,versus 17% (95% CI 7%-27%) and 78% (95% CI 66%-88%) for COL (p > 0.07). There was a percentage reduction of 75% in the AK count of the forearms treated with 5-FU (95% CI 66%-83%) and 64% in those treated with COL (95% CI 55%-72%). Regarding FPS and AKSS, there was improvement in both groups, with no difference regarding FPS (p = 0.654), and 5-FU superiority for AKSS (p = 0.012). Study limitations Single-center study. Conclusions 5-FU and COL are effective for treating CFC, with neither showing superiority regarding the reduction in AK counts. 5Fluorouracil Fluorouracil 5 5FU FU (5-FU firstline first line CFC . (CFC) COL. (COL) 05 0 0.5 randomized open selfcontrolled self controlled trial Fortyfive Forty five (9 forearms, , forearms) (AK forearm 2day day 2 /day 1 9 inclusion ≥50%, 50 ≥50% (≥50%) FPS, (FPS) (AKSS) 37 95% 95 (95 24%49% 2449 24% 49% 24 49 24%-49% 85 76%93% 7693 76% 93% 76 93 76%-93% 5FU,versus 5FUversus FUversus FU,versus 17 7%27% 727 7% 27% 7 27 7%-27% 78 66%88% 6688 66% 88% 66 88 66%-88% p 0.07. 007 0.07 07 0.07) 75 66%83% 6683 83% 83 66%-83% 64 55%72%. 5572 55% 72% 55 72 55%-72%) groups 0.654, 0654 0.654 654 0.654) 0.012. 0012 0.012 012 0.012) Singlecenter Single center study counts (CFC (COL 0. ( ≥50 (≥50% (FPS (AKSS 3 24%49 244 4 24%-49 8 76%93 769 76%-93 7%27 7%-27 66%88 668 6 66%-88 00 0.0 66%83 66%-83 55%72% 557 55%-72% 065 0.65 65 001 0.01 01 ≥5 (≥50 24%4 24%-4 76%9 76%-9 7%2 7%-2 66%8 66%-8 55%72 55%-72 06 0.6 ≥ (≥5 24%- 76%- 7%- 66%- 55%7 55%-7 (≥ 55%-

Abstract The Anais Brasileiros de Dermatologia, published since 1925, is the most influential dermatological journal in Latin America, indexed in the main international bibliographic databases, and occupies the 50th position among the 70 dermatological journals indexed in the Journal of Citations Reports, in 2022. In this article, the authors present a critical analysis of its trajectory in the last decade and compare its main bibliometric indices with Brazilian medical and international dermatological journals. The journal showed consistent growth in different bibliometric indices, which indicates a successful editorial policy and greater visibility in the international scientific community, attracting foreign authors. The increases in citations received (4.1 ×) and in the Article Influence Score (2.9×) were more prominent than those of the main Brazilian medical and international dermatological journals. The success of Anais Brasileiros de Dermatologia in the international scientific scenario depends on an assertive editorial policy, on promptly publication of high-quality articles, and on institutional stimulus to encourage clinical research in dermatology. 1925 America databases th 7 Reports 2022 article community 4.1 41 4 1 (4. × 2.9× 29 2 9 (2.9× highquality high quality articles dermatology 192 202 4. (4 2.9 (2.9 19 20 ( 2. (2. (2

Abstract Background: There are few studies dedicated to the characterization of the geriatric population with psoriasis, which has particularities in terms of clinical manifestations and therapeutic limitations. As psoriasis is a chronic disease, presenting a higher prevalence with age, the increase in life expectancy in Brazil demands knowledge about the behavior of the disease among the elderly. Objectives: To characterize elderly people with psoriasis from a tertiary service, from the clinical-epidemiological point of view, presence of comorbidities, physical frailty, and affective impact, and to compare these aspects with adults with psoriasis and elderly people without the disease. Methods: Cross-sectional study of 64 elderly patients with psoriasis, 64 adults with psoriasis, and 64 elderly patients without the disease. Clinical-demographic aspects, the Beck depression scale, and Skindex-16 were evaluated. Indicators of physical frailty were evaluated in elderly patients: handgrip, sit-to-stand test, fatigue, and weight loss >5%. Results: In the elderly, the mean age (SD) of psoriasis onset was 44 (10) years, men represented 47% of the sample, the prevalence of arthritis was 22%, and ungual involvement occurred in 72%. Topical corticosteroids were used more often among elderly people with psoriasis (100%) than among adults with the disease (86%), with no difference among other systemic treatments. Diabetes mellitus occurred in 30% of the elderly. Hypertension (59%), dyslipidemia (52%), depression (34%), and fatigue (59%) were more prevalent among the elderly with psoriasis than among the healthy controls. Background limitations Objectives service clinicalepidemiological epidemiological view comorbidities impact Methods Crosssectional Cross sectional 6 Clinicaldemographic Clinical demographic scale Skindex16 Skindex 16 Skindex-1 handgrip sittostand sit stand test 5 >5% Results SD (SD 4 10 (10 years 47 sample 22 22% 72 72% 100% 100 (100% 86%, 86 86% , (86%) treatments 30 59%, 59 59% 52%, 52 52% (52%) 34%, 34 34% (34%) (59% controls Skindex1 1 Skindex- >5 (1 2 7 (100 8 (86% 3 (52% (34% (59 > ( (86 (52 (34 (5 (8 (3

Abstract Objective This study aimed to investigate the prevalence and factors associated with olfactory dysfunction in individuals exposed to Isotretinoin (ISO) for the treatment of acne, using the University of Pennsylvania Smell Identification Test (UPSIT®). Methods This cross-sectional study enrolled age and sex-matched patients with acne who were current users of oral ISO and unexposed controls without olfactory complaints. UPSIT® and a validated questionnaire (Nasal Obstruction Symptom Evaluation) were administered to evaluate nasal obstruction in patients exposed to ISO. Results A total of seventy patients were recruited, with 35 in the exposed group and 35 in the unexposed group, consisting of 18 males and 17 females in each group, aged from 17 to 47 years. The prevalence of olfactory dysfunction was higher in the exposed group compared to the non-exposed group (62.9% vs. 17.1%), yielding a Prevalence Ratio (PR) of 3.7 (95% CI 1.9-7.1). However, no participants were categorized as anosmia or severe hyposmia and the majority of dysfunction was mild hyposmia compared to moderate hyposmia (51.5% vs. 11.4%). Among the exposed individuals, gasoline, orange, coffee, and wood exhibited the highest rates of identification errors (≥54%). Olfactory function demonstrated a negative correlation with treatment duration (p= 0.01), cumulative dose (p= 0.02), and nasal obstruction (p= 0.02). Conclusions Olfactory dysfunction was more prevalent among ISO users, despite the patients being unaware of the disorder. Olfactory changes were correlated with treatment duration, cumulative dose, and nasal obstruction. Level of evidence Level 4. (ISO UPSIT®. UPSIT . (UPSIT®) crosssectional cross sectional sexmatched sex matched complaints Nasal Evaluation recruited 3 1 4 years nonexposed non 62.9% 629 62 9 (62.9 vs 17.1%, 171 17.1% , 17.1%) PR (PR 37 7 3. 95% 95 (95 1.97.1. 1971 1.9 7.1 1.9-7.1) However 51.5% 515 51 5 (51.5 11.4%. 114 11.4% 11 11.4%) gasoline orange coffee ≥54%. 54 ≥54% (≥54%) p= p (p 0.01, 001 0.01 0 01 0.01) 0.02, 002 0.02 02 0.02) 0.02. disorder (UPSIT® 62.9 6 (62. 17.1 (9 97 1.97.1 197 19 1. 71 7. 1.9-7.1 51.5 (51. 11.4 ≥54 (≥54% 00 0.0 (UPSIT 62. (62 17. ( 1.97. 1.9-7. 51. (51 11. ≥5 (≥54 0. (6 1.97 1.9-7 (5 ≥ (≥5 1.9- (≥

Abstract Female androgenetic alopecia or female-pattern hair loss (FPHL) is highly prevalent and has a great impact on the quality of life. The treatment is a routine challenge in dermatological practice, as many therapeutic options have a limited level of evidence and often do not meet patients expectations. Lack of knowledge of the pathogenesis of the hair miniaturization process and the factors that regulate follicular morphogenesis restricts the prospect of innovative therapies. There is also a lack of randomized, controlled studies with longitudinal follow-up, using objective outcomes and exploring the performance of the available treatments and their combinations. Topical minoxidil, which has been used to treat female pattern hair loss since the 1990s, is the only medication that has a high level of evidence and remains the first choice. However, about 40% of patients do not show improvement with this treatment. In this article, the authors critically discuss the main clinical and surgical therapeutic alternatives for FPHL, as well as present camouflage methods that can be used in more extensive or unresponsive cases. femalepattern FPHL (FPHL life practice expectations therapies randomized followup, followup follow up, up follow-up combinations minoxidil 1990s s choice However 40 article cases 4